B. Riley lowered the firm’s price target on Perspective Therapeutics (CATX) to $9 from $17 and keeps a Buy rating on the shares. After taking another look at the dose-escalation data, B. Riley finds it “puzzling” how VMT-alpha-NET showed such low efficacy at 5 mCi, and uncertainty remains whether Perspective can convince the FDA to allow the 7.5 mCi dose, the analyst tells investors in a research note. If VMT-alpha-NET ends up having a similar efficacy profile as AlphaMedix, Perspective could trade at a 30%-50% enterprise value of OranoMed, B. Riley says.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital
- Perspective Therapeutics downgraded to Neutral from Buy at BofA
- Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer
- Perspective Therapeutics selloff a buying opportunity, says JonesResearch
- Perspective Therapeutics Inc trading resumes